A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 7,831 shares of VRTX stock, worth $3.64 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,831
Previous 67,385 88.38%
Holding current value
$3.64 Million
Previous $31.6 Million 88.47%
% of portfolio
0.02%
Previous 0.14%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$460.0 - $505.78 $27.4 Million - $30.1 Million
-59,554 Reduced 88.38%
7,831 $3.64 Million
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $20.4 Million - $25.3 Million
-52,059 Reduced 43.58%
67,385 $31.6 Million
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $20.8 Million - $22.8 Million
51,044 Added 74.63%
119,444 $49.9 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $21.7 Million - $26 Million
63,303 Added 1241.97%
68,400 $27.8 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $404,801 - $433,864
1,197 Added 30.69%
5,097 $1.77 Million
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $367,871 - $411,734
-1,170 Reduced 23.08%
3,900 $1.37 Million
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $1.73 Million - $1.97 Million
-6,096 Reduced 54.59%
5,070 $1.6 Million
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $4.93 Million - $5.55 Million
-17,269 Reduced 60.73%
11,166 $3.22 Million
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $8.56 Million - $9.55 Million
-31,266 Reduced 52.37%
28,435 $8.23 Million
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $6.93 Million - $8.63 Million
29,513 Added 97.76%
59,701 $16.8 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $1.76 Million - $2.08 Million
7,955 Added 35.78%
30,188 $7.88 Million
Q4 2021

Feb 10, 2022

SELL
$177.01 - $223.45 $438,276 - $553,262
-2,476 Reduced 10.02%
22,233 $4.88 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $1.13 Million - $1.27 Million
6,257 Added 33.91%
24,709 $4.48 Million
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $697,837 - $822,934
-3,722 Reduced 16.79%
18,452 $3.72 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $686,064 - $799,701
-3,314 Reduced 13.0%
22,174 $4.77 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $5.75 Million - $7.67 Million
-27,767 Reduced 52.14%
25,488 $6.02 Million
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $9.82 Million - $11.6 Million
-38,396 Reduced 41.89%
53,255 $14.5 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $1.22 Million - $1.6 Million
-5,417 Reduced 5.58%
91,651 $26.6 Million
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $9.14 Million - $11.3 Million
45,735 Added 89.09%
97,068 $23.1 Million
Q4 2019

Feb 12, 2020

BUY
$166.71 - $223.91 $6.25 Million - $8.4 Million
37,508 Added 271.31%
51,333 $11.2 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $145,451 - $163,703
875 Added 6.76%
13,825 $2.34 Million
Q2 2019

Aug 07, 2019

BUY
$164.61 - $190.37 $432,101 - $499,721
2,625 Added 25.42%
12,950 $2.38 Million
Q1 2019

May 08, 2019

BUY
$163.73 - $194.7 $609,894 - $725,257
3,725 Added 56.44%
10,325 $1.9 Million
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $3.33 Million - $4.22 Million
-21,950 Reduced 76.88%
6,600 $1.09 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $2.33 Million - $2.68 Million
-13,899 Reduced 32.74%
28,550 $5.5 Million
Q2 2018

Aug 02, 2018

BUY
$145.72 - $169.96 $4.59 Million - $5.35 Million
31,499 Added 287.66%
42,449 $7.22 Million
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $375,210 - $438,396
-2,475 Reduced 18.44%
10,950 $1.79 Million
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $10,296 - $11,666
75 Added 0.56%
13,425 $2.01 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $496,235 - $543,504
3,350 Added 33.5%
13,350 $2.03 Million
Q2 2017

Aug 14, 2017

BUY
N/A
10,000
10,000 $1.29 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.